Optimizing combination targeted immunotoxin therapy: Insights from HER2 and EpCAM expression profiles
A S Obozina1, A A Pakhomov2, A Yu Frolova2
1Moscow Center for Advanced Studies, Kulakova Str. 20, 123592, Moscow, Russia.
Abstract:
Molecular targeted cancer therapy is a rapidly developing field, driving progress toward greater treatment efficacy. However, targeted monotherapy often fails due to the development of multidrug resistance in tumors. The combination of multiple targeted agents emerges as a possible solution to enhance treatment outcomes by activating different signaling pathways. This study systematically investigates the combined effect of targeted agents for the oncomarkers HER2 and EpCAM on cancer cells. Specifically, the study examined the impact of anti-HER2 (DARP_9.29-LoPE) and anti-EpCAM (DARP_EC1-LoPE) immunotoxins on a panel of cancer cells expressing various levels of HER2 and EpCAM. Using the Chou-Talalay combination indices, the study revealed that cells with low HER2 expression and high EpCAM expression are not optimal targets for combined HER2/EpCAM therapy. In contrast, the most effective approach involves the usage of an equimolar ratio of immunotoxins for cells exhibiting high HER2 and moderate EpCAM expression, resulting in a synergistic therapeutic effect. These findings provide significant insights into optimizing combination anti-HER2/EpCAM therapies and hold promise for the development of more effective cancer treatment strategies.
Insights
Combining targeted cancer therapies HER2 and EpCAM immunotoxins shows synergistic effects in specific cancer cells. Optimal efficacy requires high HER2 and moderate EpCAM expression for improved treatment strategies.
Area of Science:
- Oncology
- Molecular Biology
- Immunotherapy
Background:
- Targeted monotherapy for cancer faces challenges due to multidrug resistance.
- Combination therapy using multiple targeted agents can overcome resistance by engaging different signaling pathways.
Purpose of the Study:
- To investigate the combined efficacy of anti-HER2 and anti-EpCAM immunotoxins on cancer cells.
- To determine optimal conditions for synergistic effects in HER2/EpCAM targeted therapy.
Main Methods:
- Utilized anti-HER2 (DARP_9.29-LoPE) and anti-EpCAM (DARP_EC1-LoPE) immunotoxins.
- Assessed effects on cancer cells with varying HER2 and EpCAM expression levels.
- Employed Chou-Talalay combination indices to evaluate synergy.
Main Results:
- Combined HER2/EpCAM therapy was less effective in cells with low HER2 and high EpCAM expression.
- Synergistic therapeutic effects were observed in cells with high HER2 and moderate EpCAM expression.
- An equimolar ratio of immunotoxins proved most effective for synergistic outcomes.
Conclusions:
- Identified specific expression levels (high HER2, moderate EpCAM) for optimal combination therapy.
- Findings guide the development of more effective dual-targeted cancer treatments.
- Optimizing combination HER2/EpCAM therapy can enhance treatment efficacy and overcome resistance.
Related Concept Videos
01:27Tumor Immunotherapy
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...